External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data.

Nastya KassirPhyllis ChanSteve DangRené Bruno

Published in: Cancer chemotherapy and pharmacology (2023)

The TGI-OS model based on unselected or PD-L1 selected NSCLC patients included in atezolizumab trials is externally validated to predict treatment effect (HR) in a biomarker-selected (ALK-positive) population included in alectinib ALEX trial suggesting that TGI-OS models may be treatment independent.

Keyphrases

small cell lung cancer
end stage renal disease
clinical trial
ejection fraction
advanced non small cell lung cancer
randomized controlled trial
study protocol
prognostic factors
big data
phase iii
phase ii
open label
brain metastases